Comparative Pharmacology
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus RISPERDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LURASIDONE HYDROCHLORIDE versus RISPERDAL.
LURASIDONE HYDROCHLORIDE vs RISPERDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lurasidone is an atypical antipsychotic that acts as a full antagonist at D2 and 5-HT2A receptors, with high affinity for 5-HT7 and 5-HT1A receptors, moderate affinity for alpha2C and alpha2A adrenergic receptors, and no appreciable affinity for H1, M1, or alpha1 receptors.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
40 mg orally once daily initially, titrated to 80 mg once daily; maximum 80 mg per day.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 14–24 hours), supporting once-daily dosing.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Approximately 80% of total radioactivity recovered in feces (67% as metabolites, 9% as unchanged drug) and 19% in urine (mostly metabolites); less than 1% excreted as unchanged parent in urine.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic